Fig 1.
Treatment plan and pattern of recurrence.
Original MRI based GTVs in blue, PET-MRGTVs in green, CTVs resembling original PTVs minus 3 mm in red and recurrent tumour volumes in follow-up MRI in purple for all patients with available follow-up MRI at recurrence. In patients 1, 4 and 7 no PET information was contained in the original target volumes.
Fig 2.
Flowchart on enrollment, allocation, follow-up and analysis of the retrospective planning study.
Table 1.
Patient and treatment characteristics.
Progression-free survival (PFS); re-treatment, post-recurrence survival (PRS) and post-recurrence progression-free survival (PR-PFS); GB—glioblastoma, AA—anaplastic astrocytoma, GTR—gross total resection, STR—subtotal resection, RT—radiotherapy, RCX—radiochemotherapy, BEV—bevacizumab, TMZ—temozolomide, PDT—photodynamic therapy.
Table 2.
Tumour volumes and planning target volumes.
Biological tumour volume (BTV), gross tumour volume (GTV) of three radiation oncologists and consensus structure (MRGTV), union of biological tumour volume with consensus gross tumour volume (PET-MRGTV) and corresponding volume with 3 mm margin, original GTV, original planning target volume (PTV) and an extracted clinical target volume (CTV).
Table 3.
Recurrence pattern in relation to original planning target volume, clinical target volume (original PTV minus 3 mm margin) and union of biological tumour volume with consensus gross tumour volume with a margins of 10, 8, 5 and 3 mm and without a margin; percentage of overlap with the volume of tumour recurrence in brackets.